search
Back to results

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients (PROPANE)

Primary Purpose

Soft Tissue Sarcoma Adult, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Propranolol
Pembrolizumab
Sponsored by
Niels Junker
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Soft Tissue Sarcoma Adult focused on measuring Immunotherapy, Propranolol, Pembrolizumab, PD-1 inhibitor, Sarcoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study Histologically confirmed diagnosis of unresectable locally advanced or metastatic Angiosarcoma or Undifferentiated Pleomorphic Sarcoma, who has progressed/failed to provide clinical benefit on first line standard chemotherapy. Age ≥18 years Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of ≤2 at the time of enrollment. Evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Available material from archived formalin-fixed paraffin-embedded tumor tissue obtained within 3 months of study enrollment for biomarker related studies. If not sufficient or available, a newly obtained core or excisional biopsy of a tumor lesion may be performed. Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L Platelet count ≥ 75 x 10⁹/L Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L) Aspartate transaminase (AST)/Alanine transaminase (ALT) ≤ 5 x ULN Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula) Women of childbearing potential (WOCBP): Agreement to use contraceptive methods with a failure rate of < 1 % per year during the treatment period and for at least 120 days after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant,contraceptive patch or contraceptive vaginal ring. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment period and for at least 120 days after the treatment. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception Exclusion Criteria: Have an anticipated life expectancy of <3 months. Moderate to severe degree of bronchial asthma or chronic obstructive pulmonary disease. Acute or non-stable congestive heart failure Any other condition listed as contraindication for treatment with propranolol according to SPC Have received any previous systemic therapy targeting the PD-1/PDL-1 signaling pathway or other immune checkpoint inhibitors. Have received propranolol within 4 weeks prior to treatment. Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks. Not recovered from the effects of previously administered agents Clinically active or unstable CNS metastases as assessed by the treating physician Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism Inclusion criteria Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study Histologically confirmed diagnosis of unresectable locally advanced or metastatic Angiosarcoma or Undifferentiated Pleomorphic Sarcoma, who has progressed/failed to provide clinical benefit on first line standard chemotherapy. Age ≥18 years Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of ≤2 at the time of enrollment. Evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Available material from archived formalin-fixed paraffin-embedded tumor tissue obtained within 3 months of study enrollment for biomarker related studies. If not sufficient or available, a newly obtained core or excisional biopsy of a tumor lesion may be performed. Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L Platelet count ≥ 75 x 10⁹/L Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L) Aspartate transaminase (AST)/Alanine transaminase (ALT) ≤ 5 x ULN Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula) Women of childbearing potential (WOCBP): Agreement to use contraceptive methods with a failure rate of < 1 % per year during the treatment period and for at least 120 days after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant,contraceptive patch or contraceptive vaginal ring. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment period and for at least 120 days after the treatment. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception Exclusion criteria Have an anticipated life expectancy of <3 months. Moderate to severe degree of bronchial asthma or chronic obstructive pulmonary disease. Acute or non-stable congestive heart failure Any other condition listed as contraindication for treatment with propranolol according to SPC Have received any previous systemic therapy targeting the PD-1/PDL-1 signaling pathway or other immune checkpoint inhibitors. Have received propranolol within 4 weeks prior to treatment. Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks. Not recovered from the effects of previously administered agents Clinically active or unstable CNS metastases as assessed by the treating physician Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) Allergies and Adverse Drug Reaction History of allergy to study drug components History of severe hypersensitivity reaction to any monoclonal antibody WOCBP who are pregnant or breastfeeding

Sites / Locations

  • Aarhus University Hospital
  • Herlev Gentofte HospitalRecruiting
  • Oslo University HospitalRecruiting
  • Karolinska University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Propranolol + pembrolizumab

Arm Description

pembrolizumab 2 mg/kg every 3 weeks and propranolol 40 mg x2 daily until progression, unacceptable toxicity or patient withdrawal for a maximum of two years.

Outcomes

Primary Outcome Measures

Progression-free survival rate
Determine the progression-free survival rate (PFSR) at 3 months by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

Secondary Outcome Measures

Objective response rate
Determine the objective response rate (ORR) using RECIST v 1.1
Duration of Response
Duration of Response (DOR) measured as time from response to progression according to RECIST v 1.1 or death.
Progression Free Survival
Progression Free Survival (PFS) according to RECIST v 1.1
Overall Survival
Overall Survival (OS).
Safety of the treatment
Toxicity will be assessed by Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. Adverse events (AEs) of interest include any grade 3 or 4 treatment-related AEs leading to discontinuation. Safety is measured through the proportion of treated patients whose worst AEs of interest occurred within safety follow up after the last treatment.
Quality of Life assessment
Determine Quality of Life (QoL) EORTC QLQ-C30

Full Information

First Posted
June 13, 2023
Last Updated
July 23, 2023
Sponsor
Niels Junker
Collaborators
Aarhus University Hospital, Oslo University Hospital, Karolinska University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05961761
Brief Title
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Acronym
PROPANE
Official Title
An Open Label Phase 2 Study on Propranolol and Pembrolizumab in Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma - a Scandinavian Sarcoma Group Collaboration
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 17, 2021 (Actual)
Primary Completion Date
January 2028 (Anticipated)
Study Completion Date
December 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Niels Junker
Collaborators
Aarhus University Hospital, Oslo University Hospital, Karolinska University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma. The main questions aims to answer: Primary: determine the progression-free survival rate (PFSR) at 3 months Secondary: determine the objective response rate (ORR), duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS). Ensure the safety and tolerability, Determine Quality of Life (QoL) • Exploratory: Characterize the TME Participants will be asked to ensure Baseline biopsy and further optional biopsies Treatment propranolol 40 mg BID and pembrolizumab 2 mg/kg Q3 weeks Evaluation, blood counts, QoL and blood samples for biomarkers according to schedule
Detailed Description
Soft tissue sarcomas (STS) are mesenchymal derived tumors consisting of more than 50 subtypes, showing high metastatic features in approximately 50% of patients with intermediate and high-grade tumors. In spite of optimizing sequence of conventional systemic treatments with chemotherapy and tyrosine kinase inhibitors with an increase in overall survival from 12 to 18 months, the prognosis has not changed and is still a dismal 8% overall survival at 5 years. After four decades doxorubicin is still first line treatment as no new drugs has proven more effective and/or less toxic. Thus, new treatment modalities are needed. Angiosarcomas (AS) and Undifferentiated Pleomorphic Sarcoma (UPS), comprising approximately 2% and 10% of STS respectively, are by definition high grade sarcomas characterized by an aggressive course. In the non-resectable advanced and metastatic setting treatment options are limited with short term palliative intent with median overall survival (OS) < 12 months. Patients are often elderly and with co-morbidities, increasing risk of severe toxicity from chemotherapy leading to significant deterioration of Quality of Life. New therapeutic options are needed. Emerging results on immune modulating therapy with immune checkpoint inhibitors (ICI), have shown promising signals of potential benefit in certain subtypes of STS, especially in UPS and AS. In tumors, neovascularization facilitate hypoxia, glucose deprivation and increased VEGF production leading to an immune suppressive tumor microenvironment (TME). This can in part be reverted by anti-angiogenic therapy including multitarget tyrosine kinase inhibitors. A proposed novel approach for targeting angiogenesis and potential immune modulatory mechanisms is through beta-adrenergic receptor (βAR) signaling. Preclinical data support combining βAR blockade with propranolol in combination with anti PD-1, and recently a phase 1 study showed the combination propranolol and pembrolizumab was well tolerated in melanoma patients. This study is an open label, Simon two-stage single arm phase 2 study of pembrolizumab and propranolol in two separate cohorts. Patients will receive pembrolizumab 2 mg/kg every 3 weeks and propranolol 40 mg x2 daily until progression, unacceptable toxicity or patient withdrawal for a maximum of two years. Up to 40 patients will be included in each separate cohort. Up to 18 patients in stage 1 and up to 22 patients in stage 2. The primary objective is to determine progression-free survival rate (PFSR) at 3 months by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) The secondary objectives are to determine objective response rate (ORR) and duration of Response (DOR) using RECIST v 1.1, PFS and OS. Ensure safety and tolerability according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0), and determine Quality of Life (QoL) using the 30 item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) questionnaire The explorative objective is to characterize the TME, immune cells and markers both in tumors and in peripheral blood.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Soft Tissue Sarcoma Adult, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma
Keywords
Immunotherapy, Propranolol, Pembrolizumab, PD-1 inhibitor, Sarcoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
A Simon´s optimum two-stage design
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Propranolol + pembrolizumab
Arm Type
Experimental
Arm Description
pembrolizumab 2 mg/kg every 3 weeks and propranolol 40 mg x2 daily until progression, unacceptable toxicity or patient withdrawal for a maximum of two years.
Intervention Type
Drug
Intervention Name(s)
Propranolol
Other Intervention Name(s)
Betablocker
Intervention Description
propranolol 40 mg x2 daily
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
anti PD-1
Intervention Description
pembrolizumab 2 mg/kg every 3 weeks
Primary Outcome Measure Information:
Title
Progression-free survival rate
Description
Determine the progression-free survival rate (PFSR) at 3 months by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Objective response rate
Description
Determine the objective response rate (ORR) using RECIST v 1.1
Time Frame
Approximately 6 months
Title
Duration of Response
Description
Duration of Response (DOR) measured as time from response to progression according to RECIST v 1.1 or death.
Time Frame
Up to 2 years
Title
Progression Free Survival
Description
Progression Free Survival (PFS) according to RECIST v 1.1
Time Frame
Up to 2 years
Title
Overall Survival
Description
Overall Survival (OS).
Time Frame
Up to 2 years
Title
Safety of the treatment
Description
Toxicity will be assessed by Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. Adverse events (AEs) of interest include any grade 3 or 4 treatment-related AEs leading to discontinuation. Safety is measured through the proportion of treated patients whose worst AEs of interest occurred within safety follow up after the last treatment.
Time Frame
Up to 2 years
Title
Quality of Life assessment
Description
Determine Quality of Life (QoL) EORTC QLQ-C30
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study Histologically confirmed diagnosis of unresectable locally advanced or metastatic Angiosarcoma or Undifferentiated Pleomorphic Sarcoma, who has progressed/failed to provide clinical benefit on first line standard chemotherapy. Age ≥18 years Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of ≤2 at the time of enrollment. Evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Available material from archived formalin-fixed paraffin-embedded tumor tissue obtained within 3 months of study enrollment for biomarker related studies. If not sufficient or available, a newly obtained core or excisional biopsy of a tumor lesion may be performed. Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L Platelet count ≥ 75 x 10⁹/L Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L) Aspartate transaminase (AST)/Alanine transaminase (ALT) ≤ 5 x ULN Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula) Women of childbearing potential (WOCBP): Agreement to use contraceptive methods with a failure rate of < 1 % per year during the treatment period and for at least 120 days after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant,contraceptive patch or contraceptive vaginal ring. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment period and for at least 120 days after the treatment. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception Exclusion Criteria: Have an anticipated life expectancy of <3 months. Moderate to severe degree of bronchial asthma or chronic obstructive pulmonary disease. Acute or non-stable congestive heart failure Any other condition listed as contraindication for treatment with propranolol according to SPC Have received any previous systemic therapy targeting the PD-1/PDL-1 signaling pathway or other immune checkpoint inhibitors. Have received propranolol within 4 weeks prior to treatment. Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks. Not recovered from the effects of previously administered agents Clinically active or unstable CNS metastases as assessed by the treating physician Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism Inclusion criteria Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study Histologically confirmed diagnosis of unresectable locally advanced or metastatic Angiosarcoma or Undifferentiated Pleomorphic Sarcoma, who has progressed/failed to provide clinical benefit on first line standard chemotherapy. Age ≥18 years Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of ≤2 at the time of enrollment. Evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). Available material from archived formalin-fixed paraffin-embedded tumor tissue obtained within 3 months of study enrollment for biomarker related studies. If not sufficient or available, a newly obtained core or excisional biopsy of a tumor lesion may be performed. Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L Platelet count ≥ 75 x 10⁹/L Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L) Aspartate transaminase (AST)/Alanine transaminase (ALT) ≤ 5 x ULN Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula) Women of childbearing potential (WOCBP): Agreement to use contraceptive methods with a failure rate of < 1 % per year during the treatment period and for at least 120 days after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant,contraceptive patch or contraceptive vaginal ring. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment period and for at least 120 days after the treatment. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception Exclusion criteria Have an anticipated life expectancy of <3 months. Moderate to severe degree of bronchial asthma or chronic obstructive pulmonary disease. Acute or non-stable congestive heart failure Any other condition listed as contraindication for treatment with propranolol according to SPC Have received any previous systemic therapy targeting the PD-1/PDL-1 signaling pathway or other immune checkpoint inhibitors. Have received propranolol within 4 weeks prior to treatment. Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks. Not recovered from the effects of previously administered agents Clinically active or unstable CNS metastases as assessed by the treating physician Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Participants with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) Allergies and Adverse Drug Reaction History of allergy to study drug components History of severe hypersensitivity reaction to any monoclonal antibody WOCBP who are pregnant or breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Niels Junker, MD, PhD
Phone
+4538682973
Email
Niels.Junker@regionh.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Niels Junker, MD, PhD
Organizational Affiliation
Herlev and Gentofte Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ninna Aggerholm Pedersen, MD, PhD, Msc
Email
aggerholm@oncology.au.dk
Facility Name
Herlev Gentofte Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niels Junker, MD, PhD
Phone
+4538682973
Email
Niels.Junker@regionh.dk
Facility Name
Oslo University Hospital
City
Oslo
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kjetil Boye, MD, PhD
Email
kjetil.boye@ous-hf.no
Facility Name
Karolinska University Hospital
City
Stockholm
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andri Papakonstantinou, MD, PhD
Email
andri.papakonstantinou@regionstockholm.se

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients

We'll reach out to this number within 24 hrs